Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PhRMA And AAM Urge New Approaches In Dealing With COVID-19 Supply Chain Disruptions

Executive Summary

As costs and delays mount, the brand and generic groups seek government solutions. AAM continues to press for federal contracts, and PhRMA wants the Department of Transportation to use its enforcement discretion under CARES Act to mandate international flights. AAM survey finds pandemic has caused 224% spike in the cost of transporting drugs.

You may also be interested in...

Planning And Communication Are Key To Managing Distribution In COVID-19 Pandemic, Experts Say

The pharmaceutical industry should use alternative transportation routes and have a business continuity plan for dealing with distribution center closures in light of the COVID-19 pandemic. They should also work closely with third-party logistics providers in ensuring drivers are complying PPE requirements.

Purchasing Commitments Must Underpin US Expansion

In an attempt to strengthen the US generic drug supply chain and reduce dependence on certain countries for supply, the AAM has proposed a policy framework “blueprint” that requires government purchasing commitments in exchange for industry manufacturing expansion.

Generic Firms Want Congress To Build On CARES Act To Prevent Critical Drug Shortages

The association for manufacturers of generics and biologics calls for public sector investment in priority medicines.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts